News

Long-term Rituxan Combo Therapy Improves Outcomes of Patients with Renal AAV, Study Shows

A combination treatment with Rituxan (rituximab), low-dose cyclophosphamide (Cytoxan), and tapered corticosteroids induces significant disease remission and reduces risk of relapse in patients with ANCA-associated vasculitis (AAV) with renal symptoms, U.K. researchers found. The study, “Long-term follow-up of a combined rituximab and cyclophosphamide regimen in…

AAV Patients in Japan on Low Daily Prednisone Doses as Maintenance Therapy Seen as More Likely to Relapse

Low daily doses of oral prednisone — 2.5 mg/day or less — during long-term remission maintenance therapy was associated with a higher rate of relapse in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Japan, a study reports. The study, “Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in…

A Case of Blood Vessel Inflammation Going from ANCA Antibody-negative to Positive

Some blood vessel inflammation cases stem from a group of diseases collectively known as ANCA-associated vasculitis, while others don’t. Chinese scientists have discovered a first: a non-ANCA-associated vasculitis case that turned into an ANCA-associated one. Doctors call an ANCA-associated case an ANCA-positive case, and a non-associated case an ANCA-negative case. At…

Questionnaire Created to Assess Patient-reported Impact of AAV on Quality of Life

Researchers developed a new questionnaire that assesses a patient’s perspective on how anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or AAV, impacts health-related quality of life. While the questionnaire should be shorter and validity testing is needed, this patient-reported measure has already helped clinicians understand which health-related outcomes matter most to…